Thus, several other immune checkpoints such as lymphocyte activation gene-3 (LAG-3), T cell immunoglobulin and mucin-domain containing-3 (TIM-3), T cell immunoglobulin and ITIM domain (TIGIT) and, as recently described by our own group, the nuclear receptor orphan NR2F6 (Nuclear receptor subfamily 2, group F, member 6; alias Ear2 and COUP-TFIII) are under investigation to address the unmet medical need for improved cancer immunotherapy. This evidence concerns the gene NR2F6 and cancer.